Table 3.
Clinical outcomes.
| Author | Post-procedural resting LVOTG (mmHg) | Post-procedural septal thickness (mm) | Post-procedural NYHA class | Number of deaths <30 days | Number of deaths >30 days | Causes of Deaths | PPMI (%) | Complications | Hospital Stay (d) | ICU stay (d) |
|---|---|---|---|---|---|---|---|---|---|---|
| Septal myectomy, age ≥18 y | ||||||||||
| Mazine et al. (12) | 16.5 ± 10.5 | 14.7 ± 2.1 | N | 0 | 1 | Non-cardiac | 20.0 | AF, AVB, LBBB, RI | 9.6 ± 9.2 | N |
| Yao et al. (13) | 6.0 ± 3.0 | 16.8 | 1.7 | 0 | 3 | Cardiac, Unknown | 5.8 | AF, AVB, LBBB | 10.5 ± 5.0 | 3.0 ± 3.0 |
| Lai et al. (14) | 11.8 ± 10.0 | 16.5 ± 3.8 | 1.6 | 4 | 1 | Sepsis, HF, LCOS, Stroke | 2.5 | LBBB | N | 2.0 ± 2.5 |
| Rastegar et al. (15) | 1.2 ± 7.0 | N | 1.4 | 4 | 11 | Cardiogenic shock, PT, Respiratory failure, HF, Systolic dysfunction, Non-cardiac | 8.9 | AF, VSD | 6.2 ± 3.1 | N |
| Vanderlaan et al. (16) | 11.0 ± 7.0 | 10.4 ± 2.6 | N | 1 | 0 | HF | 5.3 | N | 6.0 ± 1.5 | 1.4 ± 0.7 |
| An et al. (17) | 11.8 ± 10.1 | 17.0 ± 7.8 | N | 0 | 5 | SCD, HF | N | N | N | N |
| Cavigli et al. (18) | 11.0 ± 10.0 | 20.0 ± 5.0 | 1.6 | 1 | 3 | HF, Non-cardiac | 8.5 | N | N | N |
| Vrancic et al. (19) | 8.3 ± 5.4 | 13.2 ± 3.0 | N | 0 | 1 | Stroke | 14.3 | AF | 5.4 ± 2.7 | N |
| Nguyen et al. (20) | 0.0 ± 0.0 | N | 1.6 | 0 | N | None | 3.9 | N | 6.0 ± 1.5 | N |
| Afanasyev et al. (21) | 16.2 ± 8.5 | 19.3 ± 4.3 | 1.3 | 6 | 10 | Stroke, MI, MOF, PT, PE, SCD, Thromboembolism, Non-cardiac | 8.4 | AVB, PE, PT, RI, VSD | N | N |
| Antal et al. (22) | 22.5 ± 16.3 | 17.4 ± 3.1 | N | 1 | 0 | LCOS | 2.4 | AF, VSD | N | N |
| Islam et al. (23) | 8.9 ± 2.5 | 15.0 ± 1.9 | 1.0 | 0 | 0 | None | 4.8 | N | N | N |
| Lapenna et al. (24) | 9.4 ± 3.9 | N | 1.7 | 1 | 2 | LCOS, HF, SCD | 3.8 | N | N | 0.7 ± 0.2 |
| Zhu et al. (29) | 14.4 ± 12.1 | 17.9 ± 7.9 | N | 1 | 0 | HF, MOF | 2.6 | AVB, RBBB, LBBB | N | N |
| Sun et al. (25) | 9.1 ± 14.2 | 15.7 ± 4.5 | N | 2 | 6 | MOF, SCD | 1.5 | N | N | N |
| Septal myectomy, age < 18 y | ||||||||||
| Xu et al. (26) | 14.7 ± 11.5 | 16.7 ± 6.0 | 1.2 | 0 | 1 | SCD | 2.5 | N | N | 1.5 ± 1.0 |
| Laredo et al. (27) | 11.0 ± 6.6 | N | 1.3 | 5 | 3 | HF, MI | N | AVB, AVI, VSD | 15.2 ± 18.6 | 8.1 ± 17.4 |
| Schleihau et al. (28) cohort 1 | 53.3 ± 38.5 | N | 1.9 | 1 | 1 | MOF, SCD | 0 | N | 24.0 ± 19.0 | N |
| Schleihau et al. (28) cohort 2 | 8.7 ± 11.6 | N | 2.1 | 0 | 1 | HF | 9.1 | AVB | 17.0 ± 6.0 | N |
| Zhu et al. (29) | 14.4 ± 12.1 | 17.9 ± 7.9 | N | 1 | 0 | HF, MOF | 2.6 | AVB, RBBB, LBBB | 10.7 ± 14.8 | 2.3 ± 2.5 |
| Endocardial radiofrequency ablation, age ≥18 y | ||||||||||
| Lawrenz et al. (30) | 26.5 ± 22.0 | 21.4 ± 3.4 | 1.6 | 0 | 0 | None | 21.1 | PT | N | N |
| Cooper et al. (31) | 12.3 ± 2.5 | 16.8 ± 2.5 | 1.8 | 1 | 0 | Retroperitoneal hemorrhage | N | LBBB, PE | N | N |
| Crossen et al. (31) | 10.0 ± 5.4 | 20.0 | 1.8 | 0 | 0 | None | 18.2 | AVB | 1.3 ± 0.6 | N |
| Shelke et al. (33) | 42.9 ± 24.2 | N | 1.6 | 0 | 0 | None | 0 | PE | N | N |
| Beaser et al. (34) | 8.5 ± 15.1 | N | 1.4 | 0 | 0 | None | N | N | N | N |
| Zuo et al. (35) | 12.5 | 14.4 ± 2.3 | N | 0 | 0 | None | 0 | PT | N | N |
| Endocardial radiofrequency ablation, age < 18 y | ||||||||||
| Sreeram et al. (36) | 32.7 ± 27.1 | N | N | 1 | 1 | Acute left ventricular dysfunction; Arrhythmia | 6.3 | AVB, VF | 1-2 d | N |
AF, atrial fibrillation; AVB, atrioventricular block; AVI, aortic valve injury; HF, heart failure; ICU, Intensive care unit; LBBB, left bundle branch block; LCOS, low cardiac output syndrome; LVOTG, left ventricular outflow tract gradient; MI, myocardial infarction; MOF, multi-organ failure; N, not documented; NYHA, New York Heart Association; PE, pulmonary edema; PPMI, permanent pacemaker implantation; PT, pericardial tamponade; RBBB, right bundle branch block; RI, renal insufficiency; SCD, sudden cardiac death; VF, ventricular fibrillation; VSD, ventricular septal defect.